1/26/2010-Johson & Johnson (NYSE:JNJ) reported Q4 EPS of $1.02, topping consensus estimates of $0.97. Sales in the quarter rose 9% year-over-year to $16.6 billion, and...
Schlumberger Reports 13% Increase in 3Q Profit; UBS Upgrades Gilead Sciences, Wyeth, Merck, Bristol-Myers Squibb, and Schering-Plough to "Buy"; Kraft Upgraded from "Neutral" to "Buy"...
Both J&J and Genentech Boost 2008 Profit Outlooks; Johnson & Johnson 2Q US Sales Up 2%, Global Sales Up 16%; Genentech Best Biotech Performer Today,...